Cited by 702Pancreatic function and diabetesDiabetes and associated disordersCancer-related Molecular Pathways

Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in β-islet cell hyperplasia

Rane, Sushil G., Dubus, Pierre, Mettus, Richard V., Galbreath, Elizabeth J., Boden, Guenther, Reddy, E. Premkumar, Barbacid, Mariano·1999·Nature Genetics

Abstract

To ascertain the role of cyclin-dependent kinase 4 (Cdk4) in vivo, we have targeted the mouse Cdk4 locus by homologous recombination to generate two strains of mice, one that lacks Cdk4 expression and one that expresses a Cdk4 molecule with an activating mutation. Embryonic fibroblasts proliferate normally in the absence of Cdk4 but have a delayed S phase on re-entry into the cell cycle. Moreover, mice devoid of Cdk4 are viable, but small in size and infertile. These mice also develop insulin-deficient diabetes due to a reduction in beta-islet pancreatic cells. In contrast, mice expressing a mutant Cdk4 that cannot bind the cell-cycle inhibitor P16INK4a display pancreatic hyperplasia due to abnormal proliferation of beta-islet cells. These results establish Cdk4 as an essential regulator of specific cell types.

Integrity signals

Registry

Crossref · 10.1038/8751

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Inducing cell cycle arrest specifically in β-cells by p27 overexpression or postnatal Cdk4 deletion causes β-cell mass to decrease or fail to expand.

    “For instance, when cell cycle arrest is induced specifically in β-cells by overexpression of p27 [24] or by deletion of Cdk4 postnatally, β-cell mass decreases or fails to expand, which would not be the case if neogenesis or transdifferentiation were major sources of new β-cells [25,26].”

    From Expansion of β-cell mass in response to pregnancy (2010) · cites this paper as [25]

  • The tumour suppressor CDKN2A produces p16INK4a, which blocks CDK4, a key controller of pancreatic beta cell replication.

    “CDKN2A is a known tumour suppressor and its product, p16INK4a, inhibits CDK4 (cyclin-dependent kinase 4), a powerful regulator of pancreatic beta cell replication (19-21).”
  • Predicted side effects of targeted therapy may involve glucose intolerance based on pancreatic β-cell requirements for CDK4 and p16INK4a effects on islet regeneration.

    “predicted side effects of targeted therapy may involve glucose intolerance, based on requirements of pancreatic β-cells for CDK4 (85, 86) and effects of p16INK4a on age-dependent islet cell regeneration (87)”

    From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [85]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Rane, S. G., Dubus, P., Mettus, R. V., Galbreath, E. J., Boden, G., Reddy, E. P., & Barbacid, M.
Affiliations
  • Temple University (US)
  • Université Bordeaux Segalen (FR)
  • Eli Lilly (United States) (US)
  • Spanish National Cancer Research Centre (ES)
Corresponding author
  • Reddy, E. Premkumar
  • Barbacid, Mariano
Venue
Nature Genetics
Published
1999-05
Volume
22
Issue
1
Pages
44-52
ISSN
  • 1061-4036 (ISSN-L)
  • 1546-1718
OpenAlex
W1520222296
Cited by
700
References
44
Citations by year
2026: 5 · 2025: 12 · 2024: 12 · 2023: 15 · 2022: 16 · 2021: 11 · 2020: 23 · 2019: 17 · 2018: 19 · 2017: 28 · 2016: 20 · 2015: 29 · 2014: 33 · 2013: 33 · 2012: 32
FWCI
17.93
Type
journal article
Language
en
Open access
closed
Locations
  • Nature Genetics (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5r01ag007988-10, 5r01aa010221-03)
  • National Institute on Alcohol Abuse and Alcoholism (R01-AA-10221)
  • National Institute on Aging (R01-AG07988)
  • National Center for Research Resources (M01RR000349, RR-00349)
Topics
  • Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Keywords
CDK4, insulin-deficient diabetes, beta-cell hyperplasia, pancreatic islets, p16INK4a, cell cycle regulation, S phase delay, embryonic fibroblasts, infertility, cell proliferation
MeSH terms
Animals, Cell Line, Diabetes Mellitus, Enzyme Activation, Female, Gene Expression Regulation, Hyperplasia, Infertility, Female, Infertility, Male, Insulin, Islets of Langerhans, Male, Mice, Inbred Strains, Proto-Oncogene Proteins, Spermatogenesis, Mutagenesis, Site-Directed, Cyclin-Dependent Kinases, Cyclin-Dependent Kinase 4, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review